Webinars - Tempus

05/24/2024

Life Sciences

ADCs in focus: The next generation of precision medicine in oncology

Watch this engaging discussion as thought leaders explore the evolving landscape of antibody-drug conjugates (ADCs) in cancer therapeutics, including resistance mutations in first-gen ADCs, combination strategies with immune checkpoint inhibitors (ICIs), and next-gen targets and technologies. Tempus is dedicated to enhancing ADC development by offering comprehensive genomic profiling, multimodal de-identified real-world data (RWD), and AI-enabled solutions, informing target discovery and clinical trial optimization for more personalized therapies.

Speakers: Daniel Johnson, MD
Director, Precision Cancer Therapies Program, Ochsner MD Anderson Cancer Center

Funda Meric-Bernstam, MD
Chair, Department of Investigational Cancer Therapeutics (Phase I Program), MD Anderson Cancer Center

Kellogg Parsons, MD, MHS, FACS
SVP, Clinical Development, MBrace Therapeutics

Kate Sasser, PhD
Chief Scientific Officer, Tempus

Watch replay

05/14/2024

Life Sciences

Using AI to identify and close gaps in care for cancer patients

Learn how Tempus Next is helping clinicians close gaps in care for patients with cancer.

Speakers: Karen Huelsman, MS, LGC
Precision Oncology Lead and Genetic Counselor, TriHealth

Ezra Cohen, MD, FRCPSC, FASCO
Chief Medical Officer of Oncology, Tempus

Watch replay

05/08/2024

Life Sciences

Optimizing research with RWD: How Lens accelerates time to insights in drug discovery

Hear from Tempus scientists on how biopharma organizations uncover critical insights within Tempus’ multimodal database using Lens to facilitate faster-time-to-insight and accelerate research and development.

Speakers: Katie Igartua, PhD
Vice President of Translational Science, Tempus

Roosheel Patel
Senior Scientist I, Translational Research, Tempus

Ezgi Karaesmen
Director, Translational Research, Tempus

Abbas Rizvi
Director, Data Solutions, Tempus

Watch replay

04/12/2024

Providers

Liquid biopsy’s role in biomarker-driven NSCLC Management

Discover how Dr. Wade Iams of Vanderbilt University is utilizing liquid biopsy as a valuable tool for broad biomarker detection and monitoring resistance mechanisms to therapeutic pressure in NSCLC.

Speakers: Wade Iams, MD
Assistant Professor of Medicine, Vanderbilt-Ingram Cancer Center

Gary I. Grad, MD
Senior Medical Oncologist, Tempus

Ezra Cohen, MD FRCPSC, FASCO
Chief Medical Officer of Oncology, Tempus

Watch replay

04/03/2024

Providers

Leveraging RNA sequencing to identify actionable biomarkers in NSCLC management

Join us in a dynamic discussion with Dr. Marc Matrana of Ochsner Health as he shares how RNA sequencing revealed new treatment options for his patient when DNA seq was unsuccessful identifying key, actionable biomarkers.

Speakers: Marc Matrana, MD, FACP, MS
System Director of Precision Medicine, Ochsner Health

Gary I. Grad, MD
Senior Medical Oncologist, Tempus

Ezra Cohen, MD FRCPSC, FASCO
Chief Medical Officer of Oncology, Tempus

Watch replay

02/28/2024

Life Sciences

Unlocking the power of RNA in drug development

Hear insights from industry leaders on understanding, leveraging, and validating RNA in the drug development process.

Speakers: Calvin Chao, MD
SVP of Medical Affairs, Tempus

Brian Rini, MD, FASCO
Chief of Clinical Trials, Hematology & Oncology, Vanderbilt University Medical Center

Scott Haake, MD, PhD
Assistant Professor of Medicine, Hematology & Oncology, Vanderbilt University Medical Center

Nilofer Azad, MD
Professor of Oncology Co-Director, Developmental Therapeutics Program/Phase I Program Co-Leader, Cancer Genetics and Epigenetics, Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University

Watch replay

10/17/2023

Life Sciences

Impact of multimodal data in translational science

In this panel session we spoke to Translational Scientists who have been utilizing multi-modal insights in their daily work and discussed what new information can come to light by utilizing these tools.

Speakers: Iker Huerga
EVP, Life Science Strategy & RWD, Tempus

Jonathan Dry
VP, Scientific Discovery, Tempus

Charles Lin, PhD
SVP, TRN Mapping, KronosBio

Pedram Razavi, MD, PhD
Director, Breast Translational Program and Molecular Tumor Board, Memorial Sloan Kettering Cancer Center

Watch replay

09/20/2023

Providers

Evidence & guidelines-based application of PGx in mental health

Learn how evidence and guidelines-based pharmacogenomics (PGx) can be a useful tool to inform medication selection and dosing in psychiatry.

Speakers: Dr. Jon Durrani
Practicing Neurologist, Dayton Center for Neurological Disorders

Dr. Muneer Ali
Child, Adolescent and Adult Psychiatrist & Senior Director of Medical Affairs, Neuro/Psychiatry, Tempus

Watch replay

08/22/2023

Providers

The evolving landscape in precision oncology: key research findings from the 2023 ASCO Annual Meeting

Hear from Tempus moderators Dr. Ezra Cohen and Dr. Calvin Chao as they engage in a multi-disciplinary discussion around practice changing approaches to somatic and germline testing with Dr. Ramaswamy Govindan from Siteman Cancer Center and Dr. Cathy Handy Marshall from Johns Hopkins Medicine.

Speakers: Ezra Cohen, MD
Chief Medical Officer of Oncology, Tempus

Calvin Chao, MD
Senior Vice President of Medical Affairs, Tempus

Dr. Ramaswamy Govindan
Professor of Medicine, Washington University in St. Louis, Siteman Cancer Center

Catherine Handy Marshall, MD, MPH
Assistant Professor of Oncology, Johns Hopkins Medicine

Watch replay

08/18/2023

Life Sciences

An analysis on the utility of liquid biopsy (LBx) throughout clinical development

Listen to industry leaders discuss longitudinal endpoints for disease progression, the evolving role of liquid biopsy within drug development, and the value of methylation in combination with liquid biopsy.

Speakers: Nike Beaubier, MD
Senior Vice President, Life Science Pathology, Tempus

Ezra Cohen, MD
Chief Medical Officer of Oncology, Tempus

Michael Yasiejko
General Manager and Executive Vice President, Tempus

Watch replay